MARKET

EYPT

EYPT

EyePoint
NASDAQ
14.92
-0.52
-3.37%
After Hours: 14.92 0 0.00% 17:42 03/11 EDT
OPEN
15.27
PREV CLOSE
15.44
HIGH
15.65
LOW
14.88
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
3.910
MARKET CAP
1.24B
P/E (TTM)
-4.7115
1D
5D
1M
3M
1Y
5Y
1D
J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
TipRanks · 1d ago
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
TipRanks · 1d ago
EyePoint Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 2d ago
EyePoint Pharmaceuticals Price Target Raised to $35.00/Share From $31.00 by Citigroup
Dow Jones · 2d ago
Citigroup Maintains Buy on EyePoint, Raises Price Target to $35
Benzinga · 2d ago
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities
TipRanks · 2d ago
EyePoint price target raised to $35 from $31 at Citi
TipRanks · 2d ago
Weekly Report: what happened at EYPT last week (0302-0306)?
Weekly Report · 2d ago
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.